RxDoctor Payments Data

Robby Hutchinson, MD

Family Medicine · Versailles, KYNPI 1750383204

Payments from drug & device makers

$370in general payments, 2019–2025

Across 22 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$188
  • Novartis$33
  • Abbott$27
  • Upsher-smith Laboratories LLC$22
  • Merck$21
  • Astellas Pharma US Inc$20
  • plus $61 from 4 others

What the payments were for

  • Food & beverage$35596%
  • Education$164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$370 in reported general payments places this provider in the 35th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$196,364
Medicare patients
473
Services billed
3,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban261$248,449
JardianceEmpagliflozin228$219,388
TrulicityDulaglutide88$120,209
MounjaroTirzepatide70$81,376
OzempicSemaglutide39$55,192
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$54,405
RelistorMethylnaltrexone Bromide12$52,389
ArexvyRsvpref3 Antigen/As01e/Pf148$45,946
ShingrixVaricella-Zoster Ge/As01b/Pf164$36,545
FarxigaDapagliflozin Propanediol30$33,837
XareltoRivaroxaban31$32,423
EntrestoSacubitril/Valsartan40$29,696
Spiriva HandihalerTiotropium Bromide38$25,161
LinzessLinaclotide39$23,064
MyrbetriqMirabegron31$18,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arexvy, Shingrix, Incruse Ellipta$13$144,734399 claims
Novo NordiskOzempic$188$55,19239 claims
NovartisEntresto$33$29,69640 claims
Astellas Pharma US IncMyrbetriq$20$18,88631 claims
MerckJanumet Xr$21$4,71314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Versailles

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →